These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 9031469)

  • 1. PEGylation of interleukin-6 effectively increases its thrombopoietic potency.
    Tsutsumi Y; Tsunoda S; Kamada H; Kihira T; Kaneda Y; Ohsugi Y; Mayumi T
    Thromb Haemost; 1997 Jan; 77(1):168-73. PubMed ID: 9031469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
    Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A highly enhanced thrombopoietic activity by monomethoxy polyethylene glycol-modified recombinant human interleukin-6.
    Inoue H; Kadoya T; Kabaya K; Tachibana K; Nishi N; Sato M; Ohsawa M; Mikayama T; Mori KJ
    J Lab Clin Med; 1994 Oct; 124(4):529-36. PubMed ID: 7930877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective enhancement of thrombopoietic activity of PEGylated interleukin 6 by a simple procedure using a reversible amino-protective reagent.
    Tsunoda S; Ishikawa T; Watanabe M; Kamada H; Yamamoto Y; Tsutsumi Y; Hirano T; Mayumi T
    Br J Haematol; 2001 Jan; 112(1):181-8. PubMed ID: 11167800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice.
    Kamada H; Tsutsumi Y; Yamamoto Y; Kihira T; Kaneda Y; Mu Y; Kodaira H; Tsunoda SI; Nakagawa S; Mayumi T
    Cancer Res; 2000 Nov; 60(22):6416-20. PubMed ID: 11103807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice.
    Alvarez HM; So OY; Hsieh S; Shinsky-Bjorde N; Ma H; Song Y; Pang Y; Marian M; Escandón E
    Drug Metab Dispos; 2012 Feb; 40(2):360-73. PubMed ID: 22083830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent.
    Takakura T; Takimoto A; Notsu Y; Yoshida H; Ito T; Nagatome H; Ohno M; Kobayashi Y; Yoshioka T; Inagaki K; Yagi S; Hoffman RM; Esaki N
    Cancer Res; 2006 Mar; 66(5):2807-14. PubMed ID: 16510603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent.
    Tsunoda S; Ishikawa T; Yamamoto Y; Kamada H; Koizumi K; Matsui J; Tsutsumi Y; Hirano T; Mayumi T
    J Pharmacol Exp Ther; 1999 Jul; 290(1):368-72. PubMed ID: 10381801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol.
    Takagi A; Yamashita N; Yoshioka T; Takaishi Y; Sano K; Yamaguchi H; Maeda A; Saito K; Takakura Y; Hashida M
    J Control Release; 2007 Jun; 119(3):271-8. PubMed ID: 17490774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
    Yang Z; Wang J; Lu Q; Xu J; Kobayashi Y; Takakura T; Takimoto A; Yoshioka T; Lian C; Chen C; Zhang D; Zhang Y; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Sep; 64(18):6673-8. PubMed ID: 15374983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5'-phosphate supplementation.
    Sun X; Yang Z; Li S; Tan Y; Zhang N; Wang X; Yagi S; Yoshioka T; Takimoto A; Mitsushima K; Suginaka A; Frenkel EP; Hoffman RM
    Cancer Res; 2003 Dec; 63(23):8377-83. PubMed ID: 14678999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased immunorejection in unmatched blood transfusions by attachment of methoxypolyethylene glycol on human red blood cells and the effect on D antigen.
    Tan Y; Qiu Y; Xu H; Ji S; Li S; Gong F; Zhang Y
    Transfusion; 2006 Dec; 46(12):2122-7. PubMed ID: 17176324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
    Youn YS; Lee KC
    Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lecithinization of IL-6 enhances its thrombopoietic activity in mice.
    Igarashi R; Tsutsumi Y; Fujii H; Tsunoda S; Ochiai A; Takenaga M; Morizawa Y; Mayumi T; Mizushima Y
    J Pharm Pharmacol; 1997 Jan; 49(1):113-8. PubMed ID: 9120762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice.
    Ishida T; Ichikawa T; Ichihara M; Sadzuka Y; Kiwada H
    J Control Release; 2004 Mar; 95(3):403-12. PubMed ID: 15023452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
    Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin.
    Nie Y; Zhang X; Wang X; Chen J
    Bioconjug Chem; 2006; 17(4):995-9. PubMed ID: 16848407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amine-reactive pyridylhydrazone-based PEG reagents for pH-reversible PEI polyplex shielding.
    Fella C; Walker GF; Ogris M; Wagner E
    Eur J Pharm Sci; 2008 Aug; 34(4-5):309-20. PubMed ID: 18586470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyethylene-glycol conjugated recombinant human acetylcholinesterase serves as an efficacious bioscavenger against soman intoxication.
    Kronman C; Cohen O; Raveh L; Mazor O; Ordentlich A; Shafferman A
    Toxicology; 2007 Apr; 233(1-3):40-6. PubMed ID: 17045722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.
    Chen SA; Sawchuk RJ; Brundage RC; Horvath C; Mendenhall HV; Gunther RA; Braeckman RA
    J Pharmacol Exp Ther; 2000 Apr; 293(1):248-59. PubMed ID: 10734176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.